In this special report, we provide you with the latest Evaluate Vantage update on clinical and regulatory developments in the PD-(L)1 inhibitor space. Among other issues, we explore how the latest approvals could affect anti-PD-(L)1 latecomers.

Download the PD(L)anner - December 2021 for analyses and insights that draw on the latest clinical trials data as well as actionable intelligence on recent and pending regulatory action in the US, China, the EU, Japan and more.


Key upcoming catalysts in cervical cancer
Other recent US approvals and upcoming Pdufa dates
Recent approvals in China, including two first-time approvals
Regulatory state of play in Japan
Upcoming regulatory catalysts in the EU
Clinical successes and upcoming catalysts, including in liver and bile duct cancers